Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
June 02, 2025
Cyagen and Lumiere Therapeutics Forge Strategic Partnership to Advance Commercialization of the enCas12Ultra Base Editing System
Recently, Cyagen (Suzhou) Biosciences Co., Ltd. ("Cyagen") signed a strategic cooperation agreement with Lumiere Therapeutics (Suzhou) Co., Ltd. ("Lumiere") to jointly advance the commercialization of Lumiere’s enCas12Ultra. The two parties reached a licensing agreement on the patents and technology related to the high-efficiency, low off-target gene-editing tool, enCas12Ultra.

Recently, Cyagen (Suzhou) Biosciences Co., Ltd. ("Cyagen") signed a strategic cooperation agreement with Lumiere Therapeutics (Suzhou) Co., Ltd. ("Lumiere") to jointly advance the commercialization of Lumiere’s enCas12Ultra. The two parties reached a licensing agreement on the patents and technology related to the high-efficiency, low off-target gene-editing tool, enCas12Ultra.

About Lumiere’s Cas-Based Technology: enCas12Ultra

Developed by Lumiere, the enCas12Ultra protein is a cutting-edge single crRNA-mediated nuclease produced through Escherichia coli (E. coli) expression and purification. The enCas12Ultra protein specifically recognizes and cleaves DNA (dsDNA) targets with a protospacer adjacent motif (PAM) of 5'-TTN. This process creates double-strand breaks with sticky ends, facilitating knock-in and knockout gene editing in microbial, plant, and animal genomes. Compared to traditional Cas9 and Cas12 proteins, enCas12Ultra exhibits broader PAM recognition, demonstrates enhanced editing efficiency, and maintains equal or reduced off-target effects.

Figure 1: Gene targeting mechanism of the enCas12Ultra protein to perform DNA repair on a double-stranded DNA break (DSB). Donor DNA may be inserted during this process to achieve targeted gene editing.

Partnering to Advance Commercial Gene Editing

Through this collaboration, Cyagen will leverage its extensive experience and resources across genetically modified animal models, gene-edited cell models, and cell and gene therapies to support Lumiere in expanding the commercial reach of enCas12Ultra. Together, Cyagen and Lumiere aim to integrate intellectual property, technology platforms, commercialization strategies, and international business operations to establish a new paradigm for gene-editing technology services. This strategic collaboration will help propel the development of innovative therapeutic solutions and drive long-term growth in the field.

About Cyagen

Founded in 2006, Cyagen is recognized for its specialized gene edited models and CRO services supporting drug discovery and development. Utilizing advanced gene editing and disease model platforms, Cyagen provides end-to-end services from model construction to efficacy evaluation.

The company continually expands its product lines,leveraging its strengths in data and model development to offer specialized CRO service platforms for ophthalmology, neurology, and metabolic disease research. With over 900 employees and a total facility size exceeding 40,000 square meters, Cyagen is globally positioned to support drug development with excellence in research models and services.

About Lumiere Therapeutics

Established in 2021, Lumiere Therapeutics is dedicated to the research and commercialization of advanced gene editing technologies, focusing on developing innovative gene editing tools and cell and gene therapy methods. Since its founding, the Lumiere Therapeutics team has filed over ten patents covering novel gene-editing tools and delivery systems. It is one of the few companies in China to hold foundational intellectual property rights for Cas proteins, base editors, epigenetic editors, and viral-like particle (VLP) delivery systems. On January 5, 2024, Lumiere’s scientific team received patent authorization from the China National Intellectual Property Administration (CNIPA) for their proprietary "engineered adenosine deaminase and base editor," making it one of the first companies in China to secure a patent for a base editing technology with proprietary intellectual property rights.

About Cyagen
Founded in 2006, Cyagen is recognized for its specialized gene edited models and CRO services supporting drug discovery and development. Utilizing advanced gene editing and disease model platforms, Cyagen provides end-to-end services from model construction to efficacy evaluation. The company continually expands its product lines,leveraging its strengths in data and model development to offer specialized CRO service platforms for ophthalmology, neurology, and metabolic disease research. With over 900 employees and a total facility size exceeding 40,000 square meters, Cyagen is globally positioned to support drug development with excellence in research models and services.
MEDIA CONTACT
Qiming Wang Ph.D.
Director of Product Strategy and Strategic Partnerships
wangqiming@cyagen.com
Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Latest Updates
YIMA and ZIP Solutions Announce Strategic Co-Marketing Agreement for Gene Therapy
June 12, 2025
View Details
HistoWiz and Cyagen Collaborate to Streamline Histopathology for Academic and Preclinical Mouse and Rat Model Research
June 10, 2025
View Details
Cyagen and Landau Strengthen Cooperation to Accelerate the Research and Development of AI-designed AAV Gene Therapy Vectors
June 05, 2025
View Details
Cyagen and Biointron Announce Strategic Alliance to Advance Antibody Drug Discovery
June 03, 2025
View Details
Share
Top
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest